奥希替尼治疗后继发SCLC转化和ALK融合的EGFR突变型肺腺癌1例OA
A Case of EGFR-mutant Lung Adenocarcinoma with Secondary SCLC Transformation and ALK Fusion after Osimertinib Treatment
表皮生长因子受体(epidermal growth factor receptor,EGFR)基因突变是非小细胞肺癌(non-small cell lung cancer,NSCLC)最常见的驱动基因突变.本文报告1例EGFR敏感突变的肺腺癌患者,经奥希替尼一线治疗后,继发小细胞肺癌(small cell lung cancer,SCLC)转化和间变性淋巴瘤激酶(anaplastic lymphoma kinase,ALK)融合.本病例报道奥希替尼治疗后同时发生SCLC转化与ALK融合,提示二者可作为双重耐药机制并存.再次活检联合基因检测对明确耐药机制、指导个体化治疗至关重要.
Epidermal growth factor receptor(EGFR)gene mutations are the most common driver mutations in non-small cell lung cancer(NSCLC).This article reports a case of a patient with EGFR-sensitive mutant lung adenocarcinoma who developed secondary transformation to small cell lung cancer(SCLC)and anaplastic lymphoma kinase(ALK)gene fu-sion following first-line Osimertinib therapy.This paper reported a case of concurrent SCLC transformation and ALK fusion occurring after Osimertinib treatment,suggesting that the two can coexist as dual drug resistance mechanisms.Re-biopsy com-bined with genetic testing is essential for identifying drug resistance mechanisms and guiding individualized therapy.
廖丽燕;李小红
410011 长沙,中南大学湘雅二医院病理科410011 长沙,中南大学湘雅二医院病理科
肺肿瘤表皮生长因子受体间变性淋巴瘤激酶小细胞肺癌转化奥希替尼
Lung neoplasmsEpidermal growth factor receptorAnaplastic lymphoma kinaseSmall cell lung can-cer transformationOsimertinib
《中国肺癌杂志》 2026 (4)
310-314,5
评论